The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Keun Wook Lee
Honoraria - Bristol-Myers Squibb; Genexine; Lilly
Consulting or Advisory Role - Bayer
Research Funding - ALX Oncology (Inst); Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Jeeyun Lee
Consulting or Advisory Role - Oncologie; Seagen
Research Funding - AstraZeneca; Lilly; Merck Sharp & Dohme
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Jen-Shi Chen
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - AstraZeneca; Lilly; MedImmune; Merck KGaA; MSD Oncology; Ono Pharmaceutical; Roche; TTY Biopharm
 
Takaki Yoshikawa
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology
Research Funding - Lilly
 
Kenji Amagai
Research Funding - Hisamitsu Pharmaceutical (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Kun-Huei Yeh
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Ono Pharmaceutical; Takeda
 
Masahiro Goto
Honoraria - Daiichi Sankyo; Eisai; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Lilly; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yee Chao
No Relationships to Disclose
 
Ka-On Lam
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; MSD; Sanofi/Aventis; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer; Lilly; MSD
Research Funding - Bayer; Roche; Taiho Pharmaceutical (Inst)
 
Shi Rong Han
Employment - MSD K.K
 
Shinichi Shiratori
Employment - MSD K.K
Stock and Other Ownership Interests - Merck
 
Sukrut Shah
Employment - Merck
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)